## Note
nid: 1495599072939
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Pembrolizumab, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions::Pembrolizumab, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::Cancer_Immunotherapy, #AK_Step1_v11::#UWorld::10000-99999::12000-12999::12048, #AK_Step1_v11::#UWorld::10000-99999::16000-16999::16895, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::1-HighYield
markdown: false

### Text
<div>
  <div>
    {{c1::<b>Pembrolizumab</b>}} is an immunostimulant that works
    by targeting the {{c2::<b>PD-1 receptor</b>}}
  </div>
</div>

### Extra
<div>
  The PD-1/PD-L1 is an immunological checkpoint that tumors
  manipulate to evade cell mediated immunity
  <div><img src="paste-46432891437057.jpg"></div>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy
#REF!

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_3.png"></a>
</div>

### Additional Resources


### One by one

